{"title":"Ruxolitinib作为治疗顽固性瘙痒的CALR突变的原发性血小板增多症患者的选择","authors":"Cerci Kubra, Patir Pusem","doi":"10.17352/2455-5282.000167","DOIUrl":null,"url":null,"abstract":"Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.","PeriodicalId":389545,"journal":{"name":"Global Journal of Medical and Clinical Case Reports","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation\",\"authors\":\"Cerci Kubra, Patir Pusem\",\"doi\":\"10.17352/2455-5282.000167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.\",\"PeriodicalId\":389545,\"journal\":{\"name\":\"Global Journal of Medical and Clinical Case Reports\",\"volume\":\"10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Journal of Medical and Clinical Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17352/2455-5282.000167\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Journal of Medical and Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/2455-5282.000167","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation
Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
